Rafferty Asset Management
VERV

Rafferty Asset Management’s Verve Therapeutics VERV Stock Holding History

Rafferty Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-75,235
Closed -$845K – 1139
2025
Q2 		$845K Sell
75,235
-37,347
-33% -$213K ﹤0.01% 792
2025
Q1 		$515K Sell
112,582
-23,835
-17% -$160K ﹤0.01% 857
2024
Q4 		$769K Sell
136,417
-74,539
-35% -$420K ﹤0.01% 834
2024
Q3 		$1.02M Sell
210,956
-15,392
-7% -$89.4K ﹤0.01% 794
2024
Q2 		$1.1M Sell
226,348
-247,235
-52% -$1.55M ﹤0.01% 793
2024
Q1 		$6.29M Buy
473,583
+121,679
+35% +$1.61M 0.02% 418
2023
Q4 		$4.91M Buy
351,904
+32,104
+10% +$398K 0.02% 449
2023
Q3 		$4.24M Buy
319,800
+39,882
+14% +$642K 0.02% 427
2023
Q2 		$5.25M Buy
279,918
+16,880
+6% +$281K 0.03% 402
2023
Q1 		$3.79M Sell
263,038
-109,643
-29% -$2.15M 0.03% 451
2022
Q4 		$7.21M Buy
372,681
+193,914
+108% +$5.14M 0.06% 293
2022
Q3 		$6.14M Buy
+178,767
New +$5.71M 0.07% 281
2022
Q2 		– Sell
-185,009
Closed -$4.22M – 1232
2022
Q1 		$4.22M Buy
185,009
+41,635
+29% +$1.19M 0.03% 419
2021
Q4 		$5.29M Buy
+143,374
New +$6.02M 0.03% 373

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Rafferty Asset Management's VERV Position: Q3 2025 in Review

Rafferty Asset Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 75,235 shares — an estimated $845K sold.

Rafferty Asset Management first reported a position in VERV in Q4 2021 and held it in 14 quarters. The position peaked at $7.21M in Q4 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Rafferty Asset Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Rafferty Asset Management sold 75,235 Verve Therapeutics shares in Q3 2025, an estimated $845K.
  • Rafferty Asset Management first reported a position in Verve Therapeutics in Q4 2021 and held it in 14 quarters.
  • Rafferty Asset Management's Verve Therapeutics position peaked at $7.21M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Rafferty Asset Management's 13F filing for Q3 2025, filed 12 Nov 2025.